Blue Trust Inc. Has $125,000 Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN)

Blue Trust Inc. trimmed its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 27.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,153 shares of the company’s stock after selling 3,510 shares during the period. Blue Trust Inc.’s holdings in Myriad Genetics were worth $125,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. Entropy Technologies LP acquired a new stake in shares of Myriad Genetics during the 4th quarter worth approximately $178,000. Jennison Associates LLC boosted its holdings in shares of Myriad Genetics by 144.2% in the 4th quarter. Jennison Associates LLC now owns 59,015 shares of the company’s stock valued at $809,000 after purchasing an additional 34,853 shares in the last quarter. KBC Group NV boosted its holdings in shares of Myriad Genetics by 132.8% in the 4th quarter. KBC Group NV now owns 5,845 shares of the company’s stock valued at $80,000 after purchasing an additional 3,334 shares in the last quarter. Inspire Investing LLC boosted its holdings in shares of Myriad Genetics by 84.9% in the 4th quarter. Inspire Investing LLC now owns 31,373 shares of the company’s stock valued at $430,000 after purchasing an additional 14,406 shares in the last quarter. Finally, Nordea Investment Management AB boosted its stake in Myriad Genetics by 117.0% in the fourth quarter. Nordea Investment Management AB now owns 332,913 shares of the company’s stock valued at $4,548,000 after buying an additional 179,527 shares in the last quarter. 99.02% of the stock is currently owned by institutional investors and hedge funds.

Myriad Genetics Stock Down 5.3 %

Shares of NASDAQ MYGN opened at $14.19 on Friday. The company has a market capitalization of $1.29 billion, a P/E ratio of -10.92 and a beta of 1.88. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90. Myriad Genetics, Inc. has a 52-week low of $12.04 and a 52-week high of $29.30. The company’s 50 day moving average price is $13.45 and its 200-day moving average price is $19.57.

Wall Street Analysts Forecast Growth

MYGN has been the topic of a number of research analyst reports. Bank of America cut their target price on shares of Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating on the stock in a research report on Friday, December 13th. Leerink Partnrs downgraded Myriad Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, December 9th. UBS Group started coverage on Myriad Genetics in a research note on Tuesday, December 10th. They set a “neutral” rating and a $18.00 price target on the stock. Stephens reiterated an “equal weight” rating and set a $20.00 target price on shares of Myriad Genetics in a research report on Thursday, January 16th. Finally, StockNews.com downgraded shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research report on Thursday. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $22.54.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.